INTRAVENOUS (IV) IBUPROFEN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Intravenous (IV) Ibuprofen Market, By Indication (Pain Management, Fever, Others), By Strength (100 mg, 200 mg, 400 mg, 800 mg), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On February 5, 2024, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced that it had launched COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. COMBOGESIC IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID)
In February 2022, Cumberland Pharmaceuticals Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration had expanded labeling of an intravenously delivered formulation of Caldolor (ibuprofen) Injection to include use in preoperative administration. The expanded approval allows for the use of this nonnarcotic pain reliever to be administered immediately before surgery to enable patients to wake from their procedures in significantly less pain.
In January 2020, Cumberland Pharmaceuticals Inc., a pharmaceutical company, announced the launch of Caldolor (ibuprofen) Injection in a ready-to-use bag that may be administered without dilution for pain relief

Intravenous (IV) Ibuprofen Market Report Snapshots